COVID-19: drug targets and potential treatments
C Gil, T Ginex, I Maestro, V Nozal… - Journal of medicinal …, 2020 - ACS Publications
Currently, humans are immersed in a pandemic caused by the emerging severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …
respiratory syndrome coronavirus 2 (SARS-CoV-2), which threatens public health …
[HTML][HTML] Wuhan to world: the COVID-19 pandemic
COVID-19 is a Severe Acute Respiratory Syndrome (SARS), caused by SARS-CoV-2, a
novel virus which belongs to the family Coronaviridae. It was first reported in December …
novel virus which belongs to the family Coronaviridae. It was first reported in December …
Risk factors associated with in-hospital mortality in a US national sample of patients with COVID-19
N Rosenthal, Z Cao, J Gundrum, J Sianis… - JAMA network …, 2020 - jamanetwork.com
Importance Coronavirus disease 2019 (COVID-19) has infected more than 8.1 million US
residents and killed more than 221 000. There is a dearth of research on epidemiology and …
residents and killed more than 221 000. There is a dearth of research on epidemiology and …
Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia
A Greinacher, K Selleng, R Palankar… - Blood, The Journal …, 2021 - ashpublications.org
Abstract SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (AstraZeneca) causes a thromboembolic
complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using …
complication termed vaccine-induced immune thrombotic thrombocytopenia (VITT). Using …
COVID-19, mast cells, cytokine storm, psychological stress, and neuroinflammation
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China …
coronavirus 2 (SARS-CoV-2) is a new pandemic infectious disease that originated in China …
[HTML][HTML] Cardiovascular complications of COVID-19
F Farshidfar, N Koleini, H Ardehali - JCI insight, 2021 - ncbi.nlm.nih.gov
The emergence of the novel SARS coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease 2019 (COVID-19), has resulted in an unprecedented pandemic that has …
coronavirus disease 2019 (COVID-19), has resulted in an unprecedented pandemic that has …
[HTML][HTML] The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies
SARS-CoV-2 has spread across the globe in no time. In the beginning, people suffered due
to the absence of efficacious drugs required to treat severely ill patients. Nevertheless, still …
to the absence of efficacious drugs required to treat severely ill patients. Nevertheless, still …
Utilizing drug repurposing against COVID-19–efficacy, limitations, and challenges
V Parvathaneni, V Gupta - Life sciences, 2020 - Elsevier
The recent outbreak of Coronavirus disease (COVID-19), first in Eastern Asia and then
essentially across the world has been declared a pandemic by the WHO. COVID-19 is …
essentially across the world has been declared a pandemic by the WHO. COVID-19 is …
[HTML][HTML] Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19
As the COVID-19 is still growing throughout the globe, a thorough investigation into the
specific immunopathology of SARS-CoV-2, its interaction with the host immune system and …
specific immunopathology of SARS-CoV-2, its interaction with the host immune system and …
COVID-19: The potential role of copper and N-acetylcysteine (NAC) in a combination of candidate antiviral treatments against SARS-CoV-2
Background: On March 11, 2020, the World Health Organization (WHO) declared the
outbreak of coronavirus disease (COVID-19) a pandemic. Since then, thousands of people …
outbreak of coronavirus disease (COVID-19) a pandemic. Since then, thousands of people …